Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics (RAPT) Liabilities and Shareholders Equity: 2020-2023

Historic Liabilities and Shareholders Equity for Therapeutics (RAPT) over the last 4 years, with Dec 2023 value amounting to $173.3 million.

  • Therapeutics' Liabilities and Shareholders Equity fell 45.69% to $108.5 million in Q3 2024 from the same period last year, while for Sep 2024 it was $564.8 million, marking a year-over-year decrease of 39.60%. This contributed to the annual value of $173.3 million for FY2023, which is 34.89% down from last year.
  • As of FY2023, Therapeutics' Liabilities and Shareholders Equity stood at $173.3 million, which was down 34.89% from $266.2 million recorded in FY2022.
  • In the past 5 years, Therapeutics' Liabilities and Shareholders Equity ranged from a high of $266.2 million in FY2022 and a low of $119.0 million during FY2020.
  • Over the past 3 years, Therapeutics' median Liabilities and Shareholders Equity value was $198.6 million (recorded in 2021), while the average stood at $212.7 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first skyrocketed by 66.96% in 2021, then slumped by 34.89% in 2023.
  • Therapeutics' Liabilities and Shareholders Equity (Yearly) stood at $119.0 million in 2020, then surged by 66.96% to $198.6 million in 2021, then soared by 34.02% to $266.2 million in 2022, then slumped by 34.89% to $173.3 million in 2023.